|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 317.20 SEK | -3.65% |
|
-2.64% | +2.06% |
| 05-08 | US FDA Extends Review Period for BioArctic's Co-developed Alzheimer's Therapy | MT |
| 05-08 | Futures point to negative opening for Stockholm Stock Exchange (update) | FW |
Sales 2025 by Business Segment
Sales 2025 by Geography
Historical Breakdown of Revenue by Business Segments
Net Income: Breakdown by Business Segment
| Fiscal Period: December | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
Biological Products | ||||||||||
Biotechnology | 25.66M | 229M | 616M | 257M | 2B | |||||
Total Assets | 898M | 858M | 1.19B | 1.11B | 2.58B | |||||
Interest Expense | -838K | -559K | -328K | - | -2.03M | |||||
Income Tax Expense | -20.72M | 11K | 47.24M | -12.44M | 233M | |||||
CAPEX | -4.39M | -12.75M | -7.44M | -26.64M | -10.24M | |||||
EBT | -141M | -11.17M | 276M | -190M | 1.26B | |||||
Gross Profit | - | - | - | 230M | 1.94B | |||||
D&A | 13.52M | 14.18M | 7.44M | 10.72M | 15.2M | |||||
Operating Income | -140M | -17.44M | 253M | -229M | 1.26B | |||||
Net Income | -120M | -11.18M | 229M | -177M | 1.02B |
Geographical Revenue Distribution History
| Fiscal Period: December | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
North America | - | - | - | 145M | 1.32B | |||||
Asia | 14.68M | 170M | 616M | 101M | 594M | |||||
Europe | 8.47M | 58.48M | - | 11.66M | 80.15M | |||||
Others | - | - | - | 47K | 270K |
- Stock Market
- Equities
- BIOA B Stock
- Financials BioArctic AB
- Business Segments
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition